Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 87Colorectal Neoplasms 82Stomach Neoplasms 59Pancreatic Neoplasms 56Carcinoma, Non-Small-Cell Lung 46Melanoma 34Carcinoma, Renal Cell 29Neoplasm Metastasis 25Neoplasms 24Esophageal Neoplasms 24Colonic Neoplasms 22Squamous Cell Carcinoma of Head and Neck 21Carcinoma, Transitional Cell 20Liver Neoplasms 19Ovarian Neoplasms 17Adenocarcinoma Of Esophagus 17Esophageal Squamous Cell Carcinoma 16Triple Negative Breast Neoplasms 15Rectal Neoplasms 15Breast Neoplasms 14Biliary Tract Neoplasms 14Uterine Cervical Neoplasms 13Lung Neoplasms 12Cholangiocarcinoma 12Carcinoma, Merkel Cell 12Head and Neck Neoplasms 10Prostatic Neoplasms 9Gastrointestinal Neoplasms 9Small Cell Lung Carcinoma 8Endometrial Neoplasms 8

Interventions

Gemcitabine 4lenvatinib 3durvalumab 3Cisplatin 3tislelizumab 2sintilimab 2pembrolizumab 2toripalimab 1titanium silicide 1theasinensin A 1surufatinib 1sitravatinib 1regorafenib 1S 1 (combination) 1Nivolumab 1Injections 1Folfox protocol 1Fluorouracil 1Cryosurgery 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Biliary Tract Cancer × Nivolumab × Gastrointestinal × Clear all
NCT04172402 2025-07-22

NGS as the First-line Treatment in Advanced Biliary Tract Cancer

National Health Research Institutes, Taiwan

Phase 2 Completed
48 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡